click on circles to display study description...
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (n=400) vs. bevacizumab plus carboplatin and paclitaxel (n=400)
randomized controlled trial
atezolizumab and bevacizumab, carboplatin plus paclitaxel (ABCP)
atezolizumab 1200 mg every 3 weeks bevacizumab at a dose of 15 mg/kg,paclitaxel at a dose of 200 mg/m2 (175 mg for Asian patients), and carboplatin at an area under the concentration−time curve of 6 mg/ml/min
bevacizumab plus carboplatin plus paclitaxel (BCP)
bevacizumab at a dose of 15 mg per kilogram of body weight,paclitaxel at a dose of 200 mg per square meter of body-surface area (175 mg per square meter for Asian patients), and carboplatin at an areaunder the concentration−time curve of 6 mg per milliliter per minute. for four or six 21-day cycles
Crossover from the control arm to either of the experimental arms will not be permitted
non squamous - mNSCLC - L1 - all population
patients with wild type genotype (patients with EGFR or ALK genetic alterations were excluded, The Teff gene signature was defined as the expression of PD-L1, CXCL9, and IFN-γ messenger RNA
open label
240 sites in 26 countries
P3/ two sided and one interim analysis. Repartition between coprimary endoint (ABCP vs BCP) and hierarchical testing procedure with secondary endpoint and then ACP vs BCP results
The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NSCLC, regardless of PD-L1 expression and EGFR or ALK genetic alteration status, among patient with wild type (WT) and only PFS among patients with WT Teff
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (n=356) vs. bevacizumab plus carboplatin and paclitaxel (n=336)
randomized controlled trial
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP)
atezolizumab 1200 mg every 3 weeks bevacizumab at a dose of 15 mg/kg,paclitaxel at a dose of 200 mg/m2 (175 mg for Asian patients), and carboplatin at an area under the concentration−time curve of 6 mg/ml/min
bevacizumab and caroplatin plus paclitaxel (BCP)
bevacizumab at a dose of 15 mg per kilogram of body weight,paclitaxel at a dose of 200 mg per square meter of body-surface area (175 mg per square meter for Asian patients), and carboplatin at an areaunder the concentration−time curve of 6 mg per milliliter per minute.
Crossover from the control arm to either of the experimental arms will not be permitted
non squamous - mNSCLC - L1 - Wild Type (WT)
patients with wild type genotype only (patients with EGFR or ALK genetic alterations were excluded)
open label
240 sites in 26 countries
P3/ two sided and one interim analysis. Repartition between coprimary endoint (ABCP vs BCP) and hierarchical testing procedure with secondary endpoint and then ACP vs BCP results
The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NSCLC, regardless of PD-L1 expression and EGFR or ALK genetic alteration status, among patient with wild type (WT) and only PFS among patients with WT Teff
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (n=155) vs. bevacizumab plus carboplatin and paclitaxel (n=129)
randomized controlled trial
atezolizumab and bevacizumab, carboplatin plus paclitaxel (ABCP)
atezolizumab 1200 mg every 3 weeks bevacizumab at a dose of 15 mg/kg,paclitaxel at a dose of 200 mg/m2 (175 mg for Asian patients), and carboplatin at an area under the concentration−time curve of 6 mg/ml/min
bevacizumab plus carboplatin plus paclitaxel (BCP)
bevacizumab at a dose of 15 mg per kilogram of body weight,paclitaxel at a dose of 200 mg per square meter of body-surface area (175 mg per square meter for Asian patients), and carboplatin at an areaunder the concentration−time curve of 6 mg per milliliter per minute. for four or six 21-day cycles
Crossover from the control arm to either of the experimental arms will not be permitted
non squamous - mNSCLC - L1 - Wild Type (WT)
patients with wild type genotype (patients with EGFR or ALK genetic alterations were excluded, The Teff gene signature was defined as the expression of PD-L1, CXCL9, and IFN-γ messenger RNA
open label
240 sites in 26 countries
P3/ two sided and one interim analysis. Repartition between coprimary endoint (ABCP vs BCP) and hierarchical testing procedure with secondary endpoint and then ACP vs BCP results
The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NSCLC, regardless of PD-L1 expression and EGFR or ALK genetic alteration status, among patient with wild type (WT) and only PFS among patients with WT Teff
powered by vis.js Network